| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Apr―11 |
Optimization of A549 Cell Transfection Efficiency with a Plasmid Encoding the N-Protein of the SARS-CoV-2 Virus |
Yu. V. Khramtsov, T. N. Lupanova, A. A. Rosenkranz, G. P. Georgiev, A. S. Sobolev |
| 2 |
[GO] |
2024―Jul―02 |
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic |
A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Y. D. Kurochkina, Y. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A Korolev |
| 3 |
[GO] |
2024―Feb―20 |
Quantitative Description of the N-Protein of the SARS-CoV-2 Virus Degradation in Cells Stably Expressing It under the Influence of New Modular Nanotransporters |
Y. V. Khramtsov, A. V. Ulasov, T. N. Lupanova, G. P. Georgiev, A. S. Sobolev |
| 4 |
[GO] |
2024―Feb―20 |
Modular Nanotransporters Capable of Causing Intracellular Degradation of the N-Protein of the SARS-CoV-2 Virus in A549 Cells with Temporary Expression of This Protein Fused with a Fluorescent Protein mRuby3 |
Y. V. Khramtsov, A. V. Ulasov, T. N. Lupanova, G. P. Georgiev, A. S. Sobolev |
| 5 |
[GO] |
2024―Jan―08 |
Immunoliposomes As a Promising Antiviral Agent against SARS-CoV-2 |
T. V. Bobik, M. A. Simonova, N. U. Rushkevich, N. N. Kostin, G. A. Skryabin, V. D. Knorre, A. A. Schulga, E. V. Konovalova, G. M. Proshkina, A. G. Gabibov, S. M. Deev |
| 6 |
[GO] |
2023―Aug―15 |
Modular Nanotransporters Capable of Binding to SARS-CoV-2 Virus Nucleocapsid Protein in Target Cells |
Y. V. Khramtsov, A. V. Ulasov, T. N. Lupanova, G. P. Georgiev, A. S. Sobolev |
| 7 |
[GO] |
2023―Jun―20 |
Activity of nsp14 Exonuclease from SARS-CoV-2 towards RNAs with Modified 3'-Termini |
S. K. Yuyukina, A. E. Barmatov, S. N. Bizyaev, D. A. Stetsenko, O. V. Sergeeva, T. S. Zatsepin, D. O. Zharkov |
| 8 |
[GO] |
2023―Feb―14 |
Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19 |
M. Yu. Shkurnikov, D. A. Averinskaya, A. G. Komarov, I. A. Karbyshev, G. I. Speshilov, I. A. Shtinova, D. A. Doroshenko, V. I. Vechorko, O. M. Drapkina |
| 9 |
[GO] |
2023―Feb―14 |
Relationship of Covid-19 Severity with SARS-CoV-2 NS8 Protein Mutations Depending on Virus Strain |
M. Yu. Shkurnikov, D. A. Averinskaya, A. G. Komarov, I. A. Karbyshev, G. I. Speshilov, I. A. Shtinova, D. A. Doroshenko, V. I. Vechorko |
| 10 |
[GO] |
2023―Feb―14 |
Differences in Presentation of SARS-CoV-2 Omicron Strain Variant BA.1-BA.5 Peptides by HLA Molecules |
S. A. Nersisyan, M. Yu. Shkurnikov, A. P. Zhiyanov, V. O. Novosad, A. G. Tonevitsky |
| 11 |
[GO] |
2022―Dec―29 |
Properties and Activity of Peptide Derivatives of ACE2 Cellular Receptor and Their Interaction with SARS-CoV-2 S Protein Receptor-Binding Domain |
M. V. Sidorova, R. S. Bibilashvili, D. V. Avdeev, U. S. Kozhokar, M. E. Palkeeva, M. V. Ovchinnikov, A. S. Molokoedov, D. A. Shirokov, A. V. Semyonova, V. I. Uvarova, P. O. Kulyaev, E. V. Khvatov, A. A. Ignatova, A. V. Feofanov, D. I. Osolodkin, Yu. B. Porozov, L. I. Kozlovskaya, A. A. Ishmukhametov, Ye. V. Parfyonova, A. M. Egorov |
| 12 |
[GO] |
2022―Oct―27 |
Induction of Hypoxic Response in Caco-2 Cells Promote the Expression of Genes Involved in SARS-CoV-2 Endocytosis and Transcytosis |
S. A. Nersisyan |
| 13 |
[GO] |
2022―Oct―27 |
Delivery of Antibody-Like Molecules, Monobodies, Capable of Binding with SARS-CoV-2 Virus Nucleocapsid Protein, into Target Cells |
Y. V. Khramtsov, A. V. Ulasov, T. N. Lupanova, G. P. Georgiev, A. S. Sobolev |
| 14 |
[GO] |
2022―May―10 |
Among Antibody-Like Molecules, Monobodies, Able to Interact with Nucleocapsid Protein of SARS-CoV Virus, There Are Monobodies with High Affinity to Nucleocapsid Protein of SARS-CoV-2 Virus |
Y. V. Khramtsov, A. V. Ulasov, T. N. Lupanova, G. P. Georgiev, A. S. Sobolev |
| 15 |
[GO] |
2021―Dec―07 |
Antibodies to the N-Terminal Domain of Angiotensin-Converting Enzyme (ACE2) That Block Its Interaction with SARS-CoV-2 S Protein |
V. G. Krut, I. V. Astrakhantseva, S. A. Chuvpilo, G. A. Efimov, S. G. Ambaryan, M. S. Drutskaya, S. A. Nedospasov |
| 16 |
[GO] |
2021―Mar―10 |
Novel Negative Sense Genes in the RNA Genome of Coronaviruses |
O. P. Zhirnov, S. V. Poyarkov |
|
